Investor Relations

Overview

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two product candidates that are in late stage development: lefamulin, potentially the first systemic pleuromutilin antibiotic for CABP and CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Monday August 19, 2019 4:30 PM EDT
Nabriva Therapeutics Corporate Update

Tuesday August 13, 2019 9:15 AM EDT
2019 Wedbush PacGrow Healthcare Conference

Thursday June 6, 2019 4:30 PM EDT
Jefferies 2019 Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

Investor Contacts

E-mail: IR@nabriva.com